

# THNR

## Amplify Weight Loss Drug & Treatment ETF

### Analyst Report

THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

### ESG Themes and Scores

6.52/10

ESG Rate

49.08%

Global Percentile

51.23%

Peer Percentile

### Performance Data

	THNR	ETF Database Category Average	Factset Segment Average
1 Month	-0.48%	-1.02%	1.24%
3 Month	-2.25%	7.31%	-0.62%
YTD Return	-2.75%	5.63%	0.14%
1 Year Return	3.63%	13.11%	0.91%
3 Year Return	N/A	1.25%	0.00%
5 Year Return	N/A	0.12%	0.00%

### Top 5 Holdings

Symbol	Holding	% Assets
LLY	Eli Lilly and Company	14.75%
NVO	Novo Nordisk A/S Sponsored ADR Class B	14.29%
AMGN	Amgen Inc.	6.21%
ARWR	Arrowhead Pharmaceuticals, Inc.	5.70%
REGN	Regeneron Pharmaceuticals, Inc.	5.45%

### Vitals

Issuer	Amplify Investments
Brand	Amplify
Structure	N/A
Expense Ratio	0.59%
Inception	May 21, 2024
Index Tracked	VettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net

### ETF Database Themes

Category	N/A
Asset Class	Equity
Asset Class Size	N/A
Asset Class Style	N/A

### FactSet Classifications

Segment	Equity: Developed Markets Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Vanilla
Weighting	Tiered